Noticias de Eulerpool Syndax Pharmaceuticals

Syndax Pharmaceuticals Noticias de Acciones

Syndax Pharmaceuticals es observado por muchos periodistas e inversores en todo el mundo. Aquí recopilamos las noticias más recientes de Syndax Pharmaceuticals.

• 15 de enero ·

  Yahoo
  Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
• 10 de enero ·

  Yahoo
  Investing in Syndax Pharmaceuticals (NASDAQ:SNDX) five years ago would have delivered you a 53% gain
• 7 de enero ·

  Yahoo
  Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
• 9 de diciembre ·

  Yahoo
  Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
• 8 de diciembre ·

  Yahoo
  Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
• 4 de diciembre ·

  Yahoo
  Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
• 27 de noviembre ·

  Yahoo
  Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
• 18 de noviembre ·

  Yahoo
  Syndax secures FDA OK for new kind of leukemia drug
• 18 de noviembre ·

  Yahoo
  FDA approves Syndax’s Revuforj to treat leukaemia
• 15 de noviembre ·

  Yahoo
  Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation